Evidence map›Paper›PMID 33800290›Full record

ReviewInternational journal of molecular sciences2021

The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics.

Dan-In Jang, A-Hyeon Lee, Hye-Yoon Shin, Hyo-Ryeong Song, Jong-Hwi Park, Tae-Bong Kang, Sang-Ryong Lee, Seung-Hoon Yang

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 890 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
890citing papers in PubMed, 2 pooled it
158.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

890 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,539 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild-to-moderate psoriasis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Ketotifen attenuates paraquat-induced nephrotoxicity in miceResearch in pharmaceutical sciences · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. AVaccines · 2026
    Article
  20. Article

830 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Dan-In JangDepartment of Medical Biotechnology, Collage of Life Science and Biotechnology, Dongguk University, Seoul 04620, Korea.
A-Hyeon LeeDepartment of Medical Biotechnology, Collage of Life Science and Biotechnology, Dongguk University, Seoul 04620, Korea.ORCID 0000-0002-0786-1482
Hye-Yoon ShinSchool of Life Science, Handong Global University, Pohang, Gyeongbuk 37554, Korea.
Hyo-Ryeong SongDepartment of Medical Biotechnology, Collage of Life Science and Biotechnology, Dongguk University, Seoul 04620, Korea.ORCID 0000-0002-4048-0411
Jong-Hwi ParkDepartment of Medical Biotechnology, Collage of Life Science and Biotechnology, Dongguk University, Seoul 04620, Korea.
Tae-Bong KangDepartment of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju 27478, Korea.ORCID 0000-0003-1441-9470
Sang-Ryong LeeDepartment of Biological Environmental Science, Collage of Life Science and Biotechnology, Dongguk University, Seoul 04620, Korea.ORCID 0000-0002-8672-301X
Seung-Hoon YangDepartment of Medical Biotechnology, Collage of Life Science and Biotechnology, Dongguk University, Seoul 04620, Korea.ORCID 0000-0002-6880-8861
Dongguk University · KRHandong Global University · KRKonkuk University · KRYonsei University · KR

Funding

Cooperative Research Program for Agriculture Science & Technology Development of Rural Development Administration in Republic of Korea Project No. PJ014297Dongguk University Research Fund of 2019 S-2019-G0001-00009
6 · The paper itself

Abstract

Tumor necrosis factor alpha (TNF-α) was initially recognized as a factor that causes the necrosis of tumors, but it has been recently identified to have additional important functions as a pathological component of autoimmune diseases. TNF-α binds to two different receptors, which initiate signal transduction pathways. These pathways lead to various cellular responses, including cell survival, differentiation, and proliferation. However, the inappropriate or excessive activation of TNF-α signaling is associated with chronic inflammation and can eventually lead to the development of pathological complications such as autoimmune diseases. Understanding of the TNF-α signaling mechanism has been expanded and applied for the treatment of immune diseases, which has resulted in the development of effective therapeutic tools, including TNF-α inhibitors. Currently, clinically approved TNF-α inhibitors have shown noticeable potency in a variety of autoimmune diseases, and novel TNF-α signaling inhibitors are being clinically evaluated. In this review, we briefly introduce the impact of TNF-α signaling on autoimmune diseases and its inhibitors, which are used as therapeutic agents against autoimmune diseases.

Indexed as

Autoimmune DiseasesSignal TransductionTumor Necrosis Factor-alphaAnimalsChronic DiseaseHumansImmunologic FactorsImmunologic FactorsTumor Necrosis Factor-alphaautoimmune diseasesinflammatory bowel diseasepsoriatic arthritisrheumatoid arthritisTNF-αTNF-α inhibitors

Identifiers

PMID33800290
PMCPMC7962638
OpenAlexW3134454558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.